LATIN AMERICA
Algovita : the revolutionary treatment for the spinal cord The year 2016 is strategically important to Greatbatch Medical due to the FDA ’ s approval on Algovita , a complete spinal cord stimulation system able to reduce pain in the spinal column and other parts of the body . Prior to obtaining FDA approval , the European Union had already made the product available in 2015 .
Company Information
NAME
Greatbatch Medical
INDUSTRY
Medical device R & D and manufacturing
Algovita is the result of more than five years of R & D efforts and millions of dollars worth of investments .
Forecast Greatbatch ’ s acquisitions drive its medical division into a vertical integration , making the most of every new company to fulfill the corporation ’ s purposes .
Upcoming endeavors for Greatbatch Medical include brining more action to their Tijuana facilities , since the current manufacturing operation in Minnesota focused on the vascular specialty is being moved to the border city by mid-2016 . The Uruguayan operation will also see an increase in activity after engaging a new and important client , which puts Greatbatch Uruguay in position to triple its profits from where it was in 2014 .
HEADQUARTERS
Tijuana , Baja California , Mexico
FOUNDED
1970
EMPLOYEES
3,000
REVENUE
US $ 500 million
WEBSITE www . greatbatchmedical . com www . greatbatchmedical . com 77